High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition

Anngela C. Adams, Elizabeth S. Borden, Anne M. Macy, Nick Thomson, Haiyan Cui, Mark I. Gimbel, Melissa A. Wilson, Kenneth H. Buetow, Denise J. Roe, David J. Dicaudo, Jade Homsi, Karen Taraszka Hastings

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Gamma-interferon-inducible lysosomal thiol reductase (GILT) is critical for MHC class II restricted presentation of multiple melanoma antigens. There is variable GILT protein expression in malignant melanocytes in melanoma specimens. High GILT mRNA expression in melanoma specimens is associated with improved overall survival, before the advent of immune checkpoint inhibitors (ICI). However, the association of GILT in metastatic melanoma with survival in patients treated with ICI and the cell type expressing GILT associated with survival have not been determined. Using RNA sequencing datasets, high GILT mRNA expression in metastatic melanoma specimens was associated with improved progression-free and overall survival in patients treated with ICI. A clinical dataset of metastatic melanoma specimens was generated and annotated with clinical information. Positive GILT immunohistochemical staining in antigen presenting cells and melanoma cells was observed in 100% and 65% of metastatic melanoma specimens, respectively. In the subset of patients treated with ICI in the clinical dataset, high GILT protein expression within melanoma cells was associated with improved overall survival. The association of GILT mRNA and protein expression with survival was independent of cancer stage. These studies support that high GILT mRNA expression in bulk tumor samples and high GILT protein expression in melanoma cells is associated with improved survival in ICI-treated patients. These findings support further investigation of GILT as a biomarker to predict the response to ICI.

Original languageEnglish (US)
Article number2200
Issue number9
StatePublished - May 1 2022


  • GILT
  • immune checkpoint inhibitors
  • metastatic melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition'. Together they form a unique fingerprint.

Cite this